Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Oncology Sales Drive Strong Quarter For Genentech

This article was originally published in The Pink Sheet Daily

Executive Summary

Avastin and Herceptin were each up more than 70% over the prior year’s quarter.

You may also be interested in...

FDA Approves Tarceva For Pancreatic Cancer

Supplemental NDA approval for Genentech/OSI’s erlotinib, previously approved for lung cancer, follows advisory committee recommendation.

Genentech/Biogen Idec Submit Rituxan sBLA For Rheumatoid Arthritis

Filing is second in two weeks for the biologic, following recent sBLA submission for front-line non-Hodgkin's lymphoma treatment.

Avastin Pricing Strategy, Expanded Indications Under Review At Genentech

Genentech may reconsider pricing forAvastin following "phenomenal" clinical trial results evaluating the biologic for first-line non-squamous non-small cell lung cancer and metastatic breast cancer

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts